Author Correction: Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial.
作者信息
Mellinghoff Ingo K, Lu Min, Wen Patrick Y, Taylor Jennie W, Maher Elizabeth A, Arrillaga-Romany Isabel, Peters Katherine B, Ellingson Benjamin M, Rosenblum Marc K, Chun Saewon, Le Kha, Tassinari Ania, Choe Sung, Toubouti Youssef, Schoenfeld Steven, Pandya Shuchi S, Hassan Islam, Steelman Lori, Clarke Jennifer L, Cloughesy Timothy F
机构信息
Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Agios Pharmaceuticals, Cambridge, MA, USA.
出版信息
Nat Med. 2024 Jan;30(1):302. doi: 10.1038/s41591-023-02473-7.
Abstract
摘要
相似文献
1
Author Correction: Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial.作者更正：维拉唑尼和艾伏尼布治疗异柠檬酸脱氢酶1（IDH1）突变型低级别胶质瘤：一项随机围手术期1期试验。
Nat Med. 2024 Jan;30(1):302. doi: 10.1038/s41591-023-02473-7.
2
Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial.沃拉西尼布和伊沃西尼布治疗 IDH1 突变型低级别胶质瘤：一项随机、围手术期的 1 期临床试验。
Nat Med. 2023 Mar;29(3):615-622. doi: 10.1038/s41591-022-02141-2. Epub 2023 Feb 23.
3
Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial.沃拉西尼布，一种 IDH1/2 突变体的双重抑制剂，用于复发性或进行性脑胶质瘤；一项首次人体 I 期试验的结果。
Clin Cancer Res. 2021 Aug 15;27(16):4491-4499. doi: 10.1158/1078-0432.CCR-21-0611. Epub 2021 Jun 2.
4
Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial.晚期 IDH1 突变型胆管癌患者ivosidenib 的最终总生存疗效结果：III 期随机临床 ClarIDHy 试验。
JAMA Oncol. 2021 Nov 1;7(11):1669-1677. doi: 10.1001/jamaoncol.2021.3836.
5
Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma.伏立西尼（AG-881）：一种用于治疗胶质瘤的首创、可穿透血脑屏障的突变型异柠檬酸脱氢酶1和2双重抑制剂。
ACS Med Chem Lett. 2020 Jan 22;11(2):101-107. doi: 10.1021/acsmedchemlett.9b00509. eCollection 2020 Feb 13.
6
Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors.ivosidenib 的临床药代动力学和药效学：一种口服、针对突变 IDH1 的靶向抑制剂，用于治疗晚期实体瘤患者。
Invest New Drugs. 2020 Apr;38(2):433-444. doi: 10.1007/s10637-019-00771-x. Epub 2019 Apr 26.
7
Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study.ivosidenib 在 IDH1 突变型晚期胆管癌患者中的安全性和活性：一项 I 期研究。
Lancet Gastroenterol Hepatol. 2019 Sep;4(9):711-720. doi: 10.1016/S2468-1253(19)30189-X. Epub 2019 Jul 9.
8
Ivosidenib in Isocitrate Dehydrogenase 1Mutated Advanced Glioma.ivosidenib 治疗异柠檬酸脱氢酶 1 突变型高级别胶质瘤
J Clin Oncol. 2020 Oct 10;38(29):3398-3406. doi: 10.1200/JCO.19.03327. Epub 2020 Jun 12.
9
Ivosidenib, an IDH1 inhibitor, in a patient with recurrent, -mutant glioblastoma: a case report from a Phase I study.ivosidenib，一种 IDH1 抑制剂，在复发性 - 突变型胶质母细胞瘤患者中的应用：来自 I 期研究的一例病例报告。
CNS Oncol. 2020 Sep 1;9(3):CNS62. doi: 10.2217/cns-2020-0014. Epub 2020 Jul 27.
10
Validated HPLC method for simultaneous quantification of mutant IDH1/2 inhibitors (enasidenib, ivosidenib and vorasidenib) in mouse plasma: Application to a pharmacokinetic study.验证的高效液相色谱法同时定量小鼠血浆中的突变型异柠檬酸脱氢酶1/2抑制剂（恩杂鲁胺、艾伏尼布和伏拉西尼布）：在药代动力学研究中的应用
Biomed Chromatogr. 2019 Nov;33(11):e4658. doi: 10.1002/bmc.4658. Epub 2019 Sep 2.
引用本文的文献
1
Advances in IDH-mutant glioma management: IDH inhibitors, clinical implications of INDIGO trial, and future perspectives.异柠檬酸脱氢酶（IDH）突变型神经胶质瘤治疗进展：IDH抑制剂、INDIGO试验的临床意义及未来展望
Future Oncol. 2025 Jul;21(16):2089-2099. doi: 10.1080/14796694.2025.2511587. Epub 2025 May 27.
2
RNF7-Mediated ROS Targets Malignant Phenotype and Radiotherapy Sensitivity in Glioma With Different IDH1 Genotypes.RNF7介导的活性氧靶向不同IDH1基因型胶质瘤的恶性表型和放射治疗敏感性。
Mol Carcinog. 2025 Apr;64(4):652-667. doi: 10.1002/mc.23876. Epub 2025 Jan 9.
Zotero 插件